|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Uterine Cervical Neoplasm
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Esophageal carcinoma
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Uterine Cervical Neoplasm
|
|
0.710 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
ovarian neoplasm
|
|
0.710 |
GeneticVariation
|
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
Uterine Cervical Neoplasm
|
|
0.710 |
GeneticVariation
|
BEFREE |
Our cervical tumor mutational landscape shows that most mutations are found in PIK3CA (E545K, E542K) and KRAS (G12D, G13D) and others in FBXW7 (R465C, R505G, R479Q).
|
26155992 |
2015 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
|
23066039 |
2013 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
|
23888070 |
2013 |
|
ovarian neoplasm
|
|
0.710 |
CausalMutation
|
CLINVAR |
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
22271473 |
2012 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
|
Mammary Neoplasms
|
|
0.710 |
GeneticVariation
|
BEFREE |
In addition, the combined treatment of DSF and LY294002 significantly inhibited the growth of the breast tumor xenograft in nude mice induced by MDA-MB-231 cells expressing mutant PIK3CA-H1047R and PIK3CA-E545K, whereas neither DSF nor LY294002 alone could significantly retard tumor growth.
|
20424113 |
2010 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
18676830 |
2008 |
|
Esophageal carcinoma
|
|
0.710 |
GeneticVariation
|
BEFREE |
PI3K inhibitor (LY294002) inhibited the growth of an esophageal cancer cell line with a PIK3CA mutation (E545K) in vitro.
|
18262558 |
2008 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
18676830 |
2008 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
|
18725974 |
2008 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
|
15805248 |
2005 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
|
15805248 |
2005 |
|
Mammary Neoplasms
|
|
0.710 |
CausalMutation
|
CLINVAR |
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
|
15647370 |
2005 |